MedTrace Logo

Comparison of the Ability of Glulisine With Lispro to Control Type 1 Diabetes Mellitus in Children and Adolescents

NCT00115570 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 572

Last updated 2016-05-20

No results posted yet for this study

Summary

The purpose of this study is to determine if insulin glulisine (Apidra) is as safe and effective a rapid acting insulin as insulin lispro (Humalog) in children and adolescents with type 1 diabetes mellitus.

Conditions

  • Diabetes Mellitus, Insulin-Dependent

Interventions

DRUG

Insulin glulisine

Subcutaneous injection

DRUG

insulin lispro

Subcutaneous injection

DRUG

insulin glargine

Subcutaneous injection once daily

DRUG

NPH insulin

subcutaneous injection twice daily

Sponsors & Collaborators

Principal Investigators

  • Dr Arethi PHILOTHEOU · UCT Diabetes Clinical Trials Unit - Faculty of Health Sciences - South-Africa

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
4 Years
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-04-30
Primary Completion
2006-11-30
Completion
2006-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00115570 on ClinicalTrials.gov